Vivo Bio Tech Ltd Financials
Company Logo

Vivo Bio Tech Ltd Financial Statement

Vivo Bio Tech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue12.56
Operating Expense6.89
Net Profit1.37
Net Profit Margin10.91
Earning Per Share0.76
EBIDTA6.30
Effective Tax Rate13.96

Vivo Bio Tech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual46.67
Operating Expenses Annual25.88
Operating Profit Annual25.60
Interest Annual7.50
Depreciation9.02
Net Profit Annual7.57
Tax Annual1.51

Vivo Bio Tech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning1.32
Cash Flow from Operations11.83
Cash Flow from Investing-15.84
Cash Flow from Financing3.90
Cash Flow at the End1.21

Vivo Bio Tech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)47.46
PBIT Margin (%)26.76
PBT Margin (%)23.40
Net PROFIT Margin (%)5.61
Return On Networth / Equity (%)4.74
Return On Networth /Employed (%)10.06
Return On Assets (%)2.13
Total Debt / Equity (X)1.23
Asset Turnover Ratio (%)0.38

Vivo Bio Tech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual84.88
Total Current Assets Annual43.31
Non Current Assets Annual97.97
Total Shareholders Funds Annual78.19
Total Assets Annual141.29

Vivo Bio Tech Ltd Earning Calls

EPS (INR)

Expected

0.67

Reported

0.74

Surprise

10.45%

Mar 2025

EPS beaten by 10.45%

Dec 2024

EPS beaten by 11.29%

Sep 2024

EPS beaten by Infinity%

FAQS on Vivo Bio Tech Ltd Financials

As of Oct 3, 2025, Vivo Bio Tech Ltd has a market capitalization of 57.30 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Vivo Bio Tech Ltd is not with a debt-to-equity ratio of 0.66.

In FY 2024 , Vivo Bio Tech Ltd recorded a total revenue of approximately 46.67 Cr marking a significant milestone in the company's financial performance.

Vivo Bio Tech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and -0.1% annually, respectively..

Vivo Bio Tech Ltd's current PE ratio is 7.57.

Vivo Bio Tech Ltd's ROCE averaged 11.0% from the FY ending March 2023 to 2025, with a median of 10.9%. It peaked at 12.8% in March 2025, reflecting strong capital efficiency over the period..

Vivo Bio Tech Ltd's latest EBIT is Rs. 16.58 Cr, surpassing the average EBIT of Rs. 13.56 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions